Al-Azzam Sayer I, Alkhateeb Asem M, Alzoubi Karem H, Alzayadeen Raya N, Ababneh Mera A, Khabour Omar F
Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan.
Exp Ther Med. 2013 Dec;6(6):1565-1569. doi: 10.3892/etm.2013.1347. Epub 2013 Oct 15.
The aim of this study was to examine the effect of atorvastatin treatment on levels of leptin, adiponectin and insulin resistance, and their correlation with clinical parameters, in patients with type II diabetes. Patients with diabetes (n=394) were divided into two groups, comprising 161 patients who received 20 mg/day atorvastatin (statin group), and 233 patients who did not receive statins (statin-free group). The results showed that atorvastatin treatment of patients with diabetes was not associated with changes in leptin, adiponectin, the leptin/adiponectin (L/A) ratio or homeostasis model assessment-insulin resistance (HOMA-IR). However, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and total cholesterol (Tchol) were positively correlated with leptin and L/A ratio in the statin group only (P<0.05). By contrast, high-density lipoprotein cholesterol (HDL-C) showed a significant positive correlation with adiponectin in the statin and statin-free groups (P<0.05). Additionally, a positive correlation was found between HOMA-IR and glycated hemoglobin (HbA1c), and TG, in both groups, whereas Tchol was positively correlated with HOMA-IR in the statin group only (P<0.05). When multivariate analysis was performed with HOMA-IR as the dependent variable, and with adjustment for age, body mass index (BMI) and waist circumference, HbA1c was found to be a significant predictor of HOMA-IR or insulin resistance. In conclusion, atorvastatin treatment may have several effects on the interaction between leptin and adiponectin, and on clinical parameters in patients with type II diabetes.
本研究旨在探讨阿托伐他汀治疗对2型糖尿病患者瘦素、脂联素水平及胰岛素抵抗的影响，以及它们与临床参数的相关性。糖尿病患者（n = 394）被分为两组，其中161例患者接受20 mg/天阿托伐他汀治疗（他汀组），233例患者未接受他汀治疗（非他汀组）。结果显示，阿托伐他汀治疗糖尿病患者与瘦素、脂联素、瘦素/脂联素（L/A）比值或稳态模型评估-胰岛素抵抗（HOMA-IR）的变化无关。然而，仅在他汀组中，低密度脂蛋白胆固醇（LDL-C）、甘油三酯（TG）和总胆固醇（Tchol）与瘦素和L/A比值呈正相关（P<0.05）。相比之下，高密度脂蛋白胆固醇（HDL-C）在他汀组和非他汀组中均与脂联素呈显著正相关（P<0.05）。此外，两组中HOMA-IR与糖化血红蛋白（HbA1c）以及TG均呈正相关，而仅在他汀组中Tchol与HOMA-IR呈正相关（P<0.05）。以HOMA-IR为因变量进行多变量分析，并对年龄、体重指数（BMI）和腰围进行校正后，发现HbA1c是HOMA-IR或胰岛素抵抗的显著预测因子。总之，阿托伐他汀治疗可能对2型糖尿病患者瘦素与脂联素之间的相互作用以及临床参数有多种影响。
